Doctors info

Professional Overview

Dr. B. S. Srinath is one of India’s most respected surgical oncologists, whose career spanning more than five decades is defined by clinical precision, academic brilliance, and an unwavering commitment to patient care.

A gold medallist and best outgoing graduate of the University of Mysore, Dr. Srinath went on to complete his MS in Surgery at PGIMER, Chandigarh, where he received the Pfizer Gold Medal (1976). His pursuit of excellence took him to the United Kingdom, where he trained in oncology and was awarded the rare distinction of dual Fellowships of the Royal College of Surgeons (Glasgow and Edinburgh). During this period, his groundbreaking research on colonic cancer nutrition earned him the prestigious UK Government ORS Award (1981).

On returning to India, Dr. Srinath brought his expertise to premier institutions such as Tata Memorial Hospital, Kidwai Memorial Institute of Oncology, and MS Ramaiah Medical College, before establishing himself as a leading surgical oncologist at the Bangalore Institute of Oncology. Over the years, he has personally treated more than five lakh patients and performed over 60,000 complex surgeries, including Karnataka’s first Whipple’s pancreatic surgery in 1984. Renowned for his meticulous technique, he set benchmarks in surgical outcomes and infection control, consistently maintaining hospital-acquired infection rates below 1%.

Beyond the operating theatre, Dr. Srinath has been a passionate academician. He has authored more than 50 peer-reviewed publications and guided the training of over 100 postgraduate oncologists, many of whom now lead cancer programs across India. His collaborative research ties span globally reputed institutions, including the Mayo Clinic, University of Nottingham, Institute of Cancer Research (London), Maastricht University, IISc, and JNCASR.

Today, Dr. Srinath continues to balance his active surgical practice with mentorship and research, embodying the rare blend of a master surgeon, academic leader, and compassionate healer whose work has shaped the landscape of oncology in India.

Research Publications

1. Syzygium malaccense leaf extract-mediated silver nanoparticles: synthesis, characterization, and biomedical evaluation in Caenorhabditis elegans and lung cancer cell line

Authors: Bhavi SM, Thokchom B, Singh SR, Bajire SK, Shastry RP, Srinath BS, Bhat SS, Dupadahalli K, Govindasamy C, Chalekar SR, Harini BP

Journal: Green Chemistry Letters and Reviews

Published: 2025 Dec 31

Additional Details: 18(1):2456624

2. Selective De-escalation of Axillary Surgery Post Neoadjuvant Chemotherapy in Breast Cancer—Are We Ready?

Authors: Mohan A, Krishna KL, Appachu S, Hari PS, Mouli S, Srinath BS

Journal: Indian Journal of Surgical Oncology

Published: 2025 Apr 4

Additional Details: 1-0

3. Abstract P1-06-23: Extracellular matrix in Young Onset Breast Cancer–A dynamic niche as a therapeutic target

Authors: Kanyadhara LK, BS S, Srihari S, Hari PS, Veeraiyan D, Choudhary V, Zeleke WE, Sharma SS, Sarvothama M, Shetty K, Bhatt R

Journal: Clinical Cancer Research

Published: 2025 Jun 13

Additional Details: 31(12_Supplement):P1-06

4. Breast cancer cell migration is potentiated by associated fibroblasts through a laminin-511-Integrin α6β1-transduced Arp2/3 localization

Authors: Banerjee M, Mishra S, Vinukumar G, Pandhari M, Parimala DM, Sarvothama M, Korlimarla A, Srinath BS, Bhat R

Journal: bioRxiv

Published: 2025 Aug 12

Additional Details: 2025-08

5. 405P Matched primary-residual tumor analysis identifies estrogen and immune pathways as resistance mechanisms to neoadjuvant therapy in ER+/HER2+ breast cancer

Authors: Ramesh SN, Mathranda SA, Raj B, Srihari S, Devi D, BS S, Krishna DL, Korlimarla A

Journal: Annals of Oncology

Published: 2025 Sep 1

Additional Details: 36:S370

6. Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer

Authors: HP S, Paul L, Veeraiyan D, Narikot A, Veldore V, Tanwar N, Goswami H, Kumar RV, SB S, Korlimarla A

7. Selective De-escalation of Axillary Surgery Post Neoadjuvant Chemotherapy in Breast Cancer—Are We Ready?

Authors: Mohan A, Krishna KL, Appachu S, Hari PS, Mouli S, Srinath BS

Journal: Indian Journal of Surgical Oncology

Published: 2025 Apr 4

Additional Details: 1-0

8. Preliminary clinical outcomes of patients treated with vaginal brachytherapy alone using multi-channel vaginal brachytherapy applicator in operated early-stage endometrial cancer

Authors: Rishi KS, David S, Pathikonda M, Ramachandra P, Giri GV, Vadaparty A, Srinath BS

Journal: Rep Pract Oncol Radiother

Published: 2021 Feb 25

Additional Details: 26(1):43-49

9. Lower expressions of MIR34a and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment

Authors: Naskar S, Mishra I, Srinath BS, Kumar RV, Devi D, Melgiri P, Hari PS, Sashtry M, Venkatachala K, Korlimarla A

Journal: Pathology-Research and Practice

Published: 2024 Oct 14

Additional Details: 155656

10. Syringocystadenocarcinoma Papilliferum of Thigh—a Rare Cutaneous Malignancy with Unusual Histology and Clinical Presentation

Authors: Naskar S, Manohar A, HG S, V D, Kumar RV, Srinath BS

Journal: Indian Journal of Surgical Oncology

Published: 2023 Dec

Additional Details: 14(4):900-3

11. Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis

Authors: Nimbalkar VP, Snijesh VP, Rajarajan S, Alexander A, Kaluve R, Ramesh R, Srinath BS, Prabhu JS

Journal: Breast Cancer Research and Treatment

Published: 2023 Jul

Additional Details: 200(1):139-49

12. A comparative analysis of clinicopathological features and survival between pre and postmenopausal breast cancer from an Indian cohort

Authors: Nimbalkar VP, Rajarajan S, VP S, Alexander A, Kaluve R, Selvam S, Ramesh R, BS Srinath, Prabhu JS

Journal: Scientific Reports

Published: 2023 Mar 9

Additional Details: 13(1):3938

13. Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers

Authors: Korlimarla A, Hari PS, Prabhu J, Ragulan C, Patil Y, Snijesh VP, Desai K, Mathews A, Appachu S, Diwakar RB, Srinath BS

Journal: Translational Oncology

Published: 2022 Nov 1

Additional Details: 25:101511

14. 18P Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors

Authors: Nair MG, VP S, Ramesh R, BS Srinath, Prabhu JS

Journal: Annals of Oncology

Published: 2022 Nov 1

Additional Details: 33:S1436

15. 46P Co-expression of GR with PR isoforms is associated with differential prognosis in estrogen receptor-positive breast cancer

Authors: Nimbalkar VP, Snijesh VP, Rajarajan S, Patil S, Anupama CE, Ramesh R, Srinath BS, Prabhu JS

Journal: Annals of Oncology

Published: 2022 May 1

Additional Details: 33:S142

16. Abstract P5-06-14: A novel combination of a 2 gene score & TIL as a predictive Biomarker for responders to novel therapies in Indian TNBC-A population with greater proportion of TNBCs

Authors: Korlimarla A, PS H, Prabhu JS, Ragulan C, Diwakar RB, Apachu S, Cheang M, Kumar RV, Srinath BS, Sridhar TS, Rajarajan S

Journal: Cancer Research

Published: 2022 Feb 15

Additional Details: 82(4_Supplement):P5-06

17. Abstract P3-10-06: High levels of miR-18a is associated with increased proliferation but suppression of EMT phenotype in ER negative breast cancer

Authors: Nair MG, VP S, Prabhu JS, Rajarajan S, Korlimarla A, Ramesh RS, BS Srinath, TS S

Journal: Cancer Research

Published: 2022 Feb 15

Additional Details: 82(4_Supplement):P3-10

18. 38P Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis

Authors: Prabhu JS, Patil S, Rajarajan S, Ce A, Nair M, Alexander A, Ramesh R, Bs Srinath, Sridhar T

Journal: Annals of Oncology

Published: 2021 May 1

Additional Details: 32:S35

19. miR‐18a activates Wnt pathway in ER‐positive breast cancer and is associated with poor prognosis.

Authors: Nair MG, Prabhu JS, Korlimarla A, Rajarajan S, PS H, Kaul R, Alexander A, Raghavan R, BS Srinath, TS S

Journal: Cancer Medicine

Published: 2020 Aug

Additional Details: 9(15):5587-97

Languages Spoken

Kannada English Hindi Telugu Tamil Malayalam Odiya

Dr. B. S. Srinath

Professional Overview

Research Publications

1. Syzygium malaccense leaf extract-mediated silver nanoparticles: synthesis, characterization, and biomedical evaluation in Caenorhabditis elegans and lung cancer cell line

2. Selective De-escalation of Axillary Surgery Post Neoadjuvant Chemotherapy in Breast Cancer—Are We Ready?

3. Abstract P1-06-23: Extracellular matrix in Young Onset Breast Cancer–A dynamic niche as a therapeutic target

4. Breast cancer cell migration is potentiated by associated fibroblasts through a laminin-511-Integrin α6β1-transduced Arp2/3 localization

5. 405P Matched primary-residual tumor analysis identifies estrogen and immune pathways as resistance mechanisms to neoadjuvant therapy in ER+/HER2+ breast cancer

6. Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer

7. Selective De-escalation of Axillary Surgery Post Neoadjuvant Chemotherapy in Breast Cancer—Are We Ready?

8. Preliminary clinical outcomes of patients treated with vaginal brachytherapy alone using multi-channel vaginal brachytherapy applicator in operated early-stage endometrial cancer

9. Lower expressions of MIR34a and MIR31 in colo-rectal cancer are associated with an enriched immune microenvironment

10. Syringocystadenocarcinoma Papilliferum of Thigh—a Rare Cutaneous Malignancy with Unusual Histology and Clinical Presentation

11. Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis

12. A comparative analysis of clinicopathological features and survival between pre and postmenopausal breast cancer from an Indian cohort

13. Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers

14. 18P Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors

15. 46P Co-expression of GR with PR isoforms is associated with differential prognosis in estrogen receptor-positive breast cancer

16. Abstract P5-06-14: A novel combination of a 2 gene score & TIL as a predictive Biomarker for responders to novel therapies in Indian TNBC-A population with greater proportion of TNBCs

17. Abstract P3-10-06: High levels of miR-18a is associated with increased proliferation but suppression of EMT phenotype in ER negative breast cancer

18. 38P Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis

19. miR‐18a activates Wnt pathway in ER‐positive breast cancer and is associated with poor prognosis.

Languages Spoken

Book Appointment